Related Experiment Video
Updated: Mar 21, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
FAK goes nuclear to control antitumor immunity-a new target in cancer immuno-therapy
Alan Serrels1, Margaret C Frame1
1Cancer Research UK Edinburgh Center, Institute of Genetics and Molecular Medicine, University of Edinburgh , Edinburgh, UK.
Abstract:
Evading the antitumor immune response is important for the survival and progression of cancer. Recently, we identified an unexpected role for nuclear Focal Adhesion Kinase (FAK) activity in the control of tumor Treg levels and immune evasion by regulating chemokine and cytokine transcription in cancer cells. We proposed a potentially new purpose for FAK kinase inhibitors, which can cause immune-mediated tumor regression.
Insights
Cancer cells evade immune attack by controlling regulatory T cells (Tregs). Nuclear Focal Adhesion Kinase (FAK) regulates Treg levels, suggesting FAK inhibitors could promote immune-mediated tumor regression.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Tumor immune evasion is crucial for cancer progression.
- Regulatory T cells (Tregs) play a significant role in suppressing antitumor immune responses.
- Focal Adhesion Kinase (FAK) is a key signaling protein involved in cell functions.
Purpose of the Study:
- To investigate the role of nuclear Focal Adhesion Kinase (FAK) activity in regulating tumor-infiltrating regulatory T cells (Tregs).
- To explore the potential of targeting nuclear FAK activity for cancer immunotherapy.
Main Methods:
- Analysis of nuclear FAK activity in cancer cells.
- Assessment of Treg levels within tumors.
- Evaluation of chemokine and cytokine gene expression in cancer cells.
- Investigating the effects of FAK inhibitors on tumor immune microenvironment and regression.
Main Results:
- Nuclear FAK activity was found to unexpectedly control tumor Treg levels.
- FAK regulates the transcription of chemokines and cytokines in cancer cells, influencing immune evasion.
- Targeting nuclear FAK activity impacts the tumor immune microenvironment.
Conclusions:
- Nuclear FAK activity is a novel regulator of immune evasion in cancer by modulating Treg populations.
- FAK kinase inhibitors represent a potential therapeutic strategy to overcome immune suppression and induce tumor regression.
More Related Videos
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
07:42Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
Cancer
Intracellular Signaling Affects Focal Adhesions
Some...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...